The Role of Non-Statin Oral Therapies in ASCVD Risk Reduction

This episode, titled 'The Role of Non-Statin Oral Therapies in ASCVD Risk Reduction,' features expert cardiologists discussing the expanding role of non-statin oral therapies in lipid management, with a particular focus on ezetimibe and bempedoic acid as viable options for both statin-intolerant and statin-reluctant patients. The panel introduces the concept of statin reluctance to describe patients who firmly decline statin therapy regardless of clinical rationale, emphasizing that clinicians must respect patient preferences and work within those boundaries rather than risk losing the patient from care entirely. Ezetimibe is highlighted as a highly versatile agent, effective as monotherapy and as an add-on to statins, with one panelist referencing the well-established principle that doubling a statin dose yields only an additional 6% LDL reduction, making the addition of ezetimibe a far more efficient strategy for further lowering. The panel also notes that individual variability in cholesterol absorption means ezetimibe's efficacy can differ substantially between patients, reinforcing the value of a trial-based approach.

The discussion further explores bempedoic acid as a statin alternative with a favorable tolerability profile and notes its additional benefit of counteracting the diabetogenic effect associated with statin use, making it a particularly attractive option in patients at risk for diabetes. The panelists reinforce that both agents are supported by clinical outcomes trial data demonstrating reductions in cardiovascular events and emphasize that LDL lowering through any validated mechanism translates into meaningful clinical benefit. The episode closes by underscoring that there are now five distinct evidence-based pathways to reduce LDL cholesterol and cardiovascular events, offering clinicians an increasingly flexible toolkit to personalize ASCVD management across a wide range of patient profiles.

In the next episode, ‘Advancing ASCVD Management with PCSK9 Inhibitors,' panelists will continue their discussion on ASCVD and highlight the robust clinical outcomes data supporting PCSK9 inhibitor use in high and very high-risk patients, while examining how emerging oral PCSK9 inhibitors and innovative trial designs are poised to further transform the lipid-lowering treatment landscape.